专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008019144A2 THREAPEUTIC METHODS FOR TREATING VASCULAR EYE DISORDERS WITH DLL4 ANTAGONISTS 审中-公开
标题翻译：用DLL4拮抗剂治疗血管性眼病的药物治疗方法
公开(公告)号：WO2008019144A2
公开(公告)日：2008-02-14
申请号：PCT/US2007/017546
申请日：2007-08-07
申请人： REGENERON PHARMACEUTICALS, INC. , WIEGAND, Stanley, J. , PAPADOPOULOS, Nicholas, J. , LOBOV, Ivan, B.
发明人： WIEGAND, Stanley, J. , PAPADOPOULOS, Nicholas, J. , LOBOV, Ivan, B.
IPC分类号： A61K39/39
CPC分类号： C07K16/2863 , A61K38/1709 , A61K2039/505 , C07K2317/76 , C07K2319/30
摘要： A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. Preferably, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch receptor. In one embodiment, the ischemic or vascular disorder is ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension. In another embodiment, the disease treated is an eye disease or condition such as retinopathy of prematurity, ischemic retinopathy, retinal vein or artery occlusion, diabetic retinopathy, choroidal neovascularization, age related macular degeneration, corneal neovascularization, neovascular glaucoma or corneal transplantation.
摘要翻译：通过向需要的受试者施用能够抑制人类δ-样配体4（DII4）活性的试剂来治疗局部缺血或血管病症的治疗方法。优选地，该药剂是能够抑制Dll4与Notch受体结合的抗Dll4抗体或抗体片段。在一个实施方案中，缺血性或血管病症为局部缺血性损伤，脑缺血，心脏局部缺血，影响肢体和其他器官或组织的缺血性病症，动静脉畸形，伤口愈合，器官或组织移植，胎盘功能不全，动脉狭窄和闭塞，动脉粥样硬化，全身性或肺动脉高压。在另一个实施方案中，所治疗的疾病是眼疾或病症，例如早产儿视网膜病，缺血性视网膜病，视网膜静脉或动脉闭塞，糖尿病性视网膜病，脉络膜新血管生成，年龄相关性黄斑变性，角膜新血管生成，新生血管性青光眼或角膜移植。 p>

2. 发明申请

WO2014109999A1 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF 审中-公开
标题翻译：抗PDGFR-β抗体及其用途
公开(公告)号：WO2014109999A1
公开(公告)日：2014-07-17
申请号：PCT/US2014/010395
申请日：2014-01-07
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： WIEGAND, Stanley, J. , LOBOV, Ivan, B.
IPC分类号： A61K39/00 , A61K39/395 , A61P27/00 , C07K14/00 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/179 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K14/71 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/32 , C07K2319/40 , C07K2319/73 , A61K2300/00
摘要： The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.
摘要翻译：本发明提供了结合血小板衍生生长因子受体β（PDGFR-β）的抗体及其使用方法。根据本发明的某些实施方案，抗体是以高亲和力结合人PDGFR-β的完全人抗体。本发明的抗体可用于治疗与PDGFR-β信号传导和/或PDGFR-β细胞表达相关的疾病和病症，例如眼部疾病，纤维化疾病，血管疾病和癌症。

3. 发明申请

WO2018208625A1 METHODS OF TREATING EYE DISORDERS WITH APLNR ANTAGONISTS AND VEGF INHIBITORS 审中-公开
公开(公告)号：WO2018208625A1
公开(公告)日：2018-11-15
申请号：PCT/US2018/031255
申请日：2018-05-04
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： CAO, Jingtai , CHEUNG, Eunice , LOBOV, Ivan, B.
IPC分类号： A61K45/06 , A61K38/17 , A61K39/395 , C07K14/71 , C07K16/22 , A61P27/02
摘要： The present disclosure provides methods for treating, preventing or reducing the severity of an eye disease. The methods of the present disclosure comprise administering to a subject in need thereof a therapeutic composition comprising an APLNR antagonist such as an anti-APLNR antibody in combination with a vascular endothelial growth factor (VEGF) antagonist (for example, aflibercept).

4. 发明授权

EP2943218B1 ANTI-PDGFR-BETA ANTIBODIES AND USES THEREOF 有权
公开(公告)号：EP2943218B1
公开(公告)日：2018-08-08
申请号：EP14701449.2
申请日：2014-01-07
申请人： Regeneron Pharmaceuticals, Inc.
发明人： WIEGAND, Stanley, J. , LOBOV, Ivan, B.
IPC分类号： A61K39/00 , A61K39/395 , A61P27/00 , C07K14/00 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/179 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K14/71 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/32 , C07K2319/40 , C07K2319/73 , A61K2300/00
摘要： The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.

5. 发明公开

EP2943218A1 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF 有权
标题翻译：抗生素PDGFR-BETA-ANTIKÖRPER在VERWENDUNGEN
公开(公告)号：EP2943218A1
公开(公告)日：2015-11-18
申请号：EP14701449.2
申请日：2014-01-07
申请人： Regeneron Pharmaceuticals, Inc.
发明人： WIEGAND, Stanley, J. , LOBOV, Ivan, B.
IPC分类号： A61K39/00 , A61K39/395 , A61P27/00 , C07K14/00 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/179 , A61K39/39541 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K14/71 , C07K2317/21 , C07K2317/24 , C07K2317/565 , C07K2317/76 , C07K2317/77 , C07K2317/92 , C07K2317/94 , C07K2319/30 , C07K2319/32 , C07K2319/40 , C07K2319/73 , A61K2300/00
摘要： The present invention provides antibodies that bind to platelet derived growth factor receptor beta (PDGFR-beta) and methods of using the same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human PDGFR-beta with high affinity. The antibodies of the invention are useful for the treatment of diseases and disorders associated with PDGFR-beta signaling and/or PDGFR-beta cellular expression, such as ocular diseases, fibrotic diseases, vascular diseases and cancer.
摘要翻译：本发明提供了结合血小板衍生生长因子受体β（PDGFR-β）的抗体及其使用方法。根据本发明的某些实施方案，抗体是以高亲和力结合人PDGFR-β的完全人抗体。本发明的抗体可用于治疗与PDGFR-β信号传导和/或PDGFR-β细胞表达相关的疾病和病症，例如眼部疾病，纤维化疾病，血管疾病和癌症。

6. 发明公开

EP3618876A1 METHODS OF TREATING EYE DISORDERS WITH APLNR ANTAGONISTS AND VEGF INHIBITORS 审中-公开
公开(公告)号：EP3618876A1
公开(公告)日：2020-03-11
申请号：EP18729829.4
申请日：2018-05-04
申请人： Regeneron Pharmaceuticals, Inc.
发明人： CAO, Jingtai , CHEUNG, Eunice , LOBOV, Ivan, B.
IPC分类号： A61K45/06 , A61K38/17 , A61K39/395 , C07K14/71 , C07K16/22 , A61P27/02

7. 发明公开

EP2054082A2 THERAPEUTIC METHODS FOR TREATING VASCULAR EYE DISORDERS WITH DLL4 ANTAGONISTS 有权
标题翻译：使用Dll4的拮抗剂缺血性损伤或血管收缩的治疗
公开(公告)号：EP2054082A2
公开(公告)日：2009-05-06
申请号：EP07811137.4
申请日：2007-08-07
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： WIEGAND, Stanley, J. , PAPADOPOULOS, Nicholas, J. , LOBOV, Ivan, B.
IPC分类号： A61K39/39
CPC分类号： C07K16/2863 , A61K38/1709 , A61K2039/505 , C07K2317/76 , C07K2319/30
摘要： A therapeutic method for treating ischemic or vascular disorders by administering an agent capable of inhibiting human delta-like ligand 4 (DII4) activity to a subject in need thereof. Preferably, the agent is an anti-DII4 antibody or antibody fragment capable of inhibiting the binding of DII4 to a Notch receptor. In one embodiment, the ischemic or vascular disorder is ischemic injury, cerebral ischemia, cardiac ischemia, ischemic conditions affecting the limbs and other organs or tissues, arteriovenous malformations, wound healing, organ or tissue transplantation, placental insufficiency, arterial narrowing and occlusion, atherosclerosis, and systemic or pulmonary hypertension. In another embodiment, the disease treated is an eye disease or condition such as retinopathy of prematurity, ischemic retinopathy, retinal vein or artery occlusion, diabetic retinopathy, choroidal neovascularization, age related macular degeneration, corneal neovascularization, neovascular glaucoma or corneal transplantation.

8. 发明授权

EP2054082B1 Use of Dll4 antagonists in ischemic injury or vascular insufficiency 有权
标题翻译：使用Dll4的拮抗剂缺血性损伤或血管收缩的治疗
公开(公告)号：EP2054082B1
公开(公告)日：2012-12-26
申请号：EP07811137.4
申请日：2007-08-07
申请人： REGENERON PHARMACEUTICALS, INC.
发明人： WIEGAND, Stanley, J. , PAPADOPOULOS, Nicholas, J. , LOBOV, Ivan, B.
IPC分类号： A61K38/17 , A61K38/18 , C07K14/515 , C07K16/28
CPC分类号： C07K16/2863 , A61K38/1709 , A61K2039/505 , C07K2317/76 , C07K2319/30

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式